Reflecting on President Trump’s first 100 days in office
Hogan Lovells advises founding shareholders and 21 Invest on agreement for the sale of SIFI to Faes Farma
Press releases
| 13
June
2025
Milan, 13 June 2025 – Global law firm Hogan Lovells has advised the founding shareholders and 21 Invest, a European investment group founded and led by Alessandro Benetton, on the agreement for the sale of the entire share capital of SIFI S.p.A., an Italian pharmaceutical company specialized in ophthalmology, to the Spanish pharmaceutical group Faes Farma, listed on the Spanish stock exchange and leader in the fields of allergies, hypocalcemia, and immunomodulation.
SIFI S.p.A. was valued at €270 million (enterprise value), with additional deferred price components (earn-out) linked to the commercialization of the orphan drug Akantion in Europe, as well as the approval of Akantior by the FDA and subsequent sales in the USA.
SIFI S.p.A. specializes pharmaceutical products, surgical devices, and medical devices for eye care, with a product portfolio that covers the majority of ocular diseases. This transaction strengthens Faes Farma’s market position, accelerating growth and innovation in the sector.
The Hogan Lovells team that advised on the transaction was led by partner Luca Picone and included senior associate Francesco De Michele and associate Eva Campione for Corporate and M&A aspects, in collaboration with partners Derik E. Forshee and Robert F. Church, and senior associate Eva Marie Schifini of Hogan Lovells’ New York and Los Angeles offices for US pharma and FDA regulatory matters. Partner Vittorio Moresco and senior associate Giovanni Trabucco advised on employment and intellectual property aspects.
Press contacts
Press contacts
